<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202978</url>
  </required_header>
  <id_info>
    <org_study_id>Arise-FJ-R002</org_study_id>
    <nct_id>NCT04202978</nct_id>
  </id_info>
  <brief_title>Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer</brief_title>
  <official_title>Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer: One-arm Exploratory Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongshan Hospital Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongshan Hospital Xiamen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and
      radiofrequency ablation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and
      radiofrequency ablation.

      The 23 patients were enrolled in a 3-week regimen with 200mg Camrelizumab given intravenously
      every 3weeks and 250mg apatinib mesylate qd ，and 850mg/m2 capecitabine d1-14 and 130mg/m2
      oxaliplatin given intravenously d1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>6 months</time_frame>
    <description>The surgical procedure was total or subtotal proctectomy and hepatectomy with 4 cycles after Conversion therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response rate according to Response Evaluation Criteria in Solid Tumours(RECIST)1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response</measure>
    <time_frame>6 months</time_frame>
    <description>pathologic complete response (pCR)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Hepatic Metastasis of Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab+ Apatinib +XELOX +RFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab combined with Apatinib 、XELOX 、RFA in the treatment of liver metastases of colorectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab ：200mg intravenous injection d1 q3w</description>
    <arm_group_label>Camrelizumab+ Apatinib +XELOX +RFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>Apatinib：250mg/d P.O ,qd ,3weeks</description>
    <arm_group_label>Camrelizumab+ Apatinib +XELOX +RFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>capecitabine:850mg/m2 P.O ,bid ,d1-d14</description>
    <arm_group_label>Camrelizumab+ Apatinib +XELOX +RFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>oxaliplatin:130mg/m2 intravenous injection d1 q3w</description>
    <arm_group_label>Camrelizumab+ Apatinib +XELOX +RFA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <description>radiofrequency ablation:between first cycle and second cycle percutaneous</description>
    <arm_group_label>Camrelizumab+ Apatinib +XELOX +RFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 75 years

          -  Confirmed by pathology (including histology or cytology) as metastatic colorectal
             adenocarcinoma of the liver (no other metastatic sites)

          -  Confirmed by CT/MRI/PET - CT/ultrasound examination of liver metastases, the liver
             metastases number 3 or higher, and the multidisciplinary team (MDT) confirmed for
             unresectable liver metastases;

          -  Patients with at least one evaluable or measurable lesions as per RECIST version 1.1
             （CT scan length and diameter of tumor lesion≥10mm，CT scan of lymph node lesion was
             short diameter≥15mm，scan slice thickness 5mm；）

          -  ECOG（Eastern Cooperative Oncology Group）PS（Performance Status）:0-2 scores

          -  The expected survival time is more than 3 months

          -  The main organ function is normal, which should meet the following criteria:

             (1) blood routine examination standards should be met（no blood transfusion within 14
             days）

             a．HB≥ 90g/L b. WBC≥3×109/L c. ANC≥1.5×109/L d. PLT≥100×109/L （2）biochemical
             examination shall comply with the following criteria：

               1. BIL＜1.5 normal upper limit ULN

               2. ALT and AST≤5 ULN

               3. Cr≤1.5 ULN，CCR（creatinine clearance rate）≥50ml/min(Cockcroft-Gault formula)

          -  Women of childbearing age must have a pregnancy test in 7 days before entering the
             group (in serum), and the results were negative, and willing to use appropriate
             contraception during the study period and the last 8 weeks after giving drug test; men
             should have the surgical sterilization, or adopt the appropriate contraceptive methods
             during the test and the last 8 weeks after giving drug test。

          -  Participants is willing to participate in this study, sign the informed consent, have
             good compliance, cooperate with follow-up.

        Exclusion Criteria:

          -  Participants is willing to participate in this study, sign the informed consent, have
             good compliance, cooperate with follow-up.

          -  Any other malignancy was diagnosed within the first 5 years of the study, except
             locally treatable and cured basal cell or squamous cell carcinoma of the skin,
             superficial bladder cancer, carcinoma in situ of the cervix, carcinoma in situ of the
             breast duct, and papillary carcinoma of the thyroid.

          -  Patients who had received anti-tumor therapy, including chemotherapy, radiotherapy,
             surgery, endocrine therapy, biological therapy, tumor embolization, targeted therapy
             and immunotherapy (pd-1 / pd-l1 antibody, anti-pd-l2 antibody, anti-cd137 antibody,
             ctla-4 antibody, or other drugs/antibodies acting on T cell co-stimulation or
             checkpoint pathway) within 28 days before enrollment.

          -  Accompanied by serious heart, lung, liver, kidney disease; Have nerve, mental disease;
             obstruction of the digestive tract with severe infection.

          -  Distant metastases to sites other than the liver.

          -  The blood pressure of patients with hypertension cannot be reduced to the normal range
             by the antihypertensive drugs (systolic pressure &gt;140 mmHg, diastolic pressure &gt;90
             mmHg)

          -  Patients have a clear tendency with gastrointestinal bleeding, including the following
             situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena
             and hematemesis history in 2 months; and patients with fecal occult blood (+) and
             unresected gastric primary tumor; patients with the risk of bleeding should take the
             gastroscopy test, if it is the gastric cancer, and researchers believe that may
             results in massive digestive tract hemorrhage；coagulation dysfunction
             (INR(international normalized ratio)&gt;1.5, APTT(activated partial thromboplastin
             time)&gt;1.5 ULN), with bleeding tendency

          -  pregnant or lactating women

          -  A history of immunodeficiency, including HIV testing positive, or other acquired or
             congenital immunodeficiency disorders, or a history of organ transplantation and
             allogeneic bone marrow transplantation

          -  Presence of interstitial lung disease, non-infectious pneumonia, or uncontrolled
             systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, and acute
             pneumonia)

          -  Patients are positive of urine protein (urine protein detection 2+ or above, or 24
             hours urine protein quantitative &gt;1.0g)

          -  Patients with a history of cardiovascular and cerebrovascular diseases who are still
             taking oral thrombolytic drugs or anticoagulant drugs

          -  Patients with uncontrolled epilepsy, central nervous system disease, or mental
             disorders whose clinical severity, as determined by the investigator, may prevent the
             signing of the informed consent or have multiple factors that affect oral medications
             (such as inability to swallow, persistent uncontrolled nausea and vomiting, chronic
             diarrhea, and intestinal obstruction)

          -  A person who has previously been allergic to any component of camrilizumab or to any
             component of the drug under study

          -  Patients who participate in other clinical studies before or during treatment

          -  The researchers consider those who were not suitable for inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wu wei xin, doctor</last_name>
    <phone>13950103647</phone>
    <phone_ext>0592</phone_ext>
    <email>wu3170536@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu wei xin, Doctor</last_name>
      <phone>13950103647</phone>
      <phone_ext>0592</phone_ext>
      <email>wu3175036@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

